noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

related announcements

News

Karyopharm Therapeutics Inc.

Treatment of Severe COVID 19 with Low Dose Selinexor: Demonstration of[...]
Karyopharm Therapeutics Inc.

PAK4 Inhibition Improves PD-1 Blockade Immunotherapy
Karyopharm Therapeutics Inc.

Eltanexor (KPT 8602), a Second Generation Selective Inhibitor of[...]

Healthcare

Results

Karyopharm Therapeutics Inc.

09/06/2017 | Press release | Archived content

A First in Human Phase 1 Study of KPT-9274, a First in Class Dual Inhibitor of PAK4 and NAMPT, in Patients with Advanced Solid Malignancies or NHL

Sharing and Personal Tools

Please select the service you want to use: